Read More Pharma Industry News Why Wall Street and clinicians may be watching IKT-001 more closely after the Phase 3 launch Could IKT-001 change the PAH treatment landscape? Read why Inhibikase Therapeutics’ Phase 3 launch could become a major 2026 biotech catalyst. bySoujanya RaviApril 11, 2026